Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Microtubule destabilizing agent-3, negative control

Catalog No. TYD-05354 Copy Product Info
🥰Excellent
Microtubule destabilizing agent-3, negative control, is an analog of B32B3 and serves as the negative control for Microtubule destabilizing agent-3. This agent functions as a microtubule destabilizer by disrupting microtubule stability, which promotes mitotic arrest and exhibits an anti-myeloma phenotype, ultimately leading to cell death. It can also induce G2/M phase arrest and caspase-dependent apoptosis.

Microtubule destabilizing agent-3, negative control

Copy Product Info
🥰Excellent
Catalog No. TYD-05354

Microtubule destabilizing agent-3, negative control, is an analog of B32B3 and serves as the negative control for Microtubule destabilizing agent-3. This agent functions as a microtubule destabilizer by disrupting microtubule stability, which promotes mitotic arrest and exhibits an anti-myeloma phenotype, ultimately leading to cell death. It can also induce G2/M phase arrest and caspase-dependent apoptosis.

Microtubule destabilizing agent-3, negative control
Cas No. 2734582-91-1
Pack SizePriceUSA StockGlobal StockQuantity
10 mgInquiryInquiryInquiry
50 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Microtubule destabilizing agent-3, negative control, is an analog of B32B3 and serves as the negative control for Microtubule destabilizing agent-3. This agent functions as a microtubule destabilizer by disrupting microtubule stability, which promotes mitotic arrest and exhibits an anti-myeloma phenotype, ultimately leading to cell death. It can also induce G2/M phase arrest and caspase-dependent apoptosis.
In vitro
Microtubule destabilizing agent-3, negative control (VPR4), does not demonstrate thermal stabilization of DCAF1 in CETSA.
In vivo
The study utilized C57Bl/6 and B6.SJL-Ptprca Pepcb/BoyJ (Ptprca) mice. A dosage of 15 mg/kg was administered intraperitoneally (i.p.) over a regimen of 5 consecutive days followed by a 2-day break. Results demonstrated a reduction in lymphoma progression biomarkers, such as spleen weight and peripheral blood and nodal tumor burden. Ten days of continued treatment significantly increased overall survival, extending the median from 17 days in the vehicle group to 22 days in the VPR8 group. The compound was effective in both tp53 wild-type and tp53-null EμMyc lymphoma models.
Chemical Properties
Molecular Weight310.42
FormulaC17H18N4S
Cas No.2734582-91-1
SmilesN(=CC=1C=CC=CC1)NC=2N=CN=C3SC4CCCCC4C32
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year

Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Microtubule destabilizing agent-3, negative control | purchase Microtubule destabilizing agent-3, negative control | Microtubule destabilizing agent-3, negative control cost | order Microtubule destabilizing agent-3, negative control | Microtubule destabilizing agent-3, negative control in vivo | Microtubule destabilizing agent-3, negative control in vitro | Microtubule destabilizing agent-3, negative control formula | Microtubule destabilizing agent-3, negative control molecular weight